Cellosaurus logo
expasy logo

Cellosaurus CCRF-CEM (CVCL_0207)

[Text version]
Cell line name CCRF-CEM
Accession CVCL_0207
Resource Identification Initiative To cite this cell line use: CCRF-CEM (RRID:CVCL_0207)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Part of: NCI-60 cancer cell line panel.
Part of: NCI-7 clinical proteomics reference material cell line panel.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8436.
Population: Caucasian.
Doubling time: 23 hours (PubMed=17117183); 24 hours (PubMed=20922763); 22.0 hours (PubMed=25070259); ~24 hours (CLS=300147); ~24-30 hours (DSMZ=ACC-240); 26.7 hours (NCI-DTP=CCRF-CEM).
Microsatellite instability: Instable (MSI-low) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: Metabolome analysis.
Omics: lncRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: T-cell; CL=CL_0000084.
Sequence variations
  • Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (PubMed=14500364; PubMed=17308084).
  • Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (PubMed=11565033; Cosmic-CLP=905952; DepMap=ACH-001738).
  • Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP=905952; DepMap=ACH-001738).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP=905952; DepMap=ACH-001738).
  • Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (PubMed=15472075).
  • Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (PubMed=15472075).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (PubMed=2144611; PubMed=10071127; PubMed=17088437; Cosmic-CLP=905952; DepMap=ACH-001738).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=2144611; PubMed=10071127; PubMed=17088437; Cosmic-CLP=905952; DepMap=ACH-001738).
HLA typing Source: PubMed=15748285
Class I
Class II

Source: IPD-IMGT/HLA=10403
Class II

Source: CLS=300147
Class I
Class II

Source: DSMZCellDive=ACC-240
Class I
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.21
East Asian, North0.43
East Asian, South0.09
South Asian0.81
European, North69.4
European, South28.85
Disease Childhood T acute lymphoblastic leukemia (NCIt: C7953)
Precursor T-cell acute lymphoblastic leukemia (ORDO: Orphanet_99861)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_2265 (1301)CVCL_6869 (6T-CEM)CVCL_D101 (AG-F)
CVCL_D544 (CCRF/ADR5000)CVCL_4V17 (CCRF/CEM/ara-C/3A)CVCL_4V18 (CCRF/CEM/ara-C/7A)
CVCL_D546 (CCRF/VCR1000)CVCL_6244 (CEM A3.01)CVCL_V186 (CEM cl13)
CVCL_4V21 (CEM/ara-C)CVCL_A5TX (CEM/ara-G)CVCL_3496 (CEM/C1)
CVCL_D597 (CEM/VLB10)CVCL_3932 (CEM/VLB100)CVCL_4V12 (CEM/VLB500)
CVCL_4V09 (CEM/VLB55)CVCL_1B35 (CEM/VM-1)CVCL_7905 (CEMR.3)
CVCL_J653 (CO)CVCL_8865 (EU-7)CVCL_8265 (MKB-1)
CVCL_L808 (RC-2A)CVCL_GZ11 (TUB-4D)CVCL_8276 (UTMB-460)
Sex of cell Female
Age at sampling 3Y11M
Category Cancer cell line
STR profile Source(s): AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980

CSF1PO9,10,11 (RCB=RCB1980)
10,11 (AddexBio=C0003001/32; ATCC=CCL-119; Cosmic-CLP=905952; KCLB=10119; PubMed=20922763)
10,11,12 (JCRB=IFO50412; JCRB=JCRB9023)
10,13 (ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240)
11 (ECACC=85112105; JCRB=JCRB0033; PubMed=19372543)
D2S133823,24 (DSMZ=ACC-240)
24 (ATCC=CCL-119; PubMed=19372543; PubMed=20922763)
D3S135814,15 (CLS=300147; DSMZ=ACC-240; KCLB=10119)
15 (ATCC=CCL-119; PubMed=19372543)
15,16 (PubMed=20922763)
D5S81812,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980)
12,13,14 (Cosmic-CLP=905952)
D7S8209,12 (JCRB=JCRB0033)
9,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980)
D8S117912,13 (CLS=300147; DSMZ=ACC-240; PubMed=20922763)
13 (ATCC=CCL-119; PubMed=19372543)
D13S31710,11,12 (RCB=RCB1980)
11 (ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240)
11,12 (AddexBio=C0003001/32; ATCC=CCL-119; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763)
D16S53910,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; PubMed=19372543; PubMed=20922763)
10,13,14 (RCB=RCB1980)
D18S5113 (DSMZ=ACC-240)
13,18 (ATCC=CCL-119; CLS=300147)
D21S1130,33.2 (ATCC=CCL-119; PubMed=19372543; PubMed=20922763)
30,34.2 (CLS=300147; DSMZ=ACC-240)
FGA22,23,24,25 (DSMZ=ACC-240)
23,24 (ATCC=CCL-119; CLS=300147; PubMed=20922763)
24 (PubMed=19372543)
Penta D10,11 (CLS=300147; DSMZ=ACC-240)
11 (ATCC=CCL-119)
Penta E5 (DSMZ=ACC-240)
5,14 (ATCC=CCL-119; CLS=300147)
TPOX7,8 (DSMZ=ACC-240)
8 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980)
vWA17,18,19 (DSMZ=ACC-240)
17,19 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763)
18,19 (RCB=RCB1980)

Run an STR similarity search on this cell line
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm

PubMed=14278051; DOI=10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J
Foley G.E., Lazarus H., Farber S., Uzman B.G., Boone B.A., McCarthy R.E.
Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia.
Cancer 18:522-529(1965)

PubMed=5224274; DOI=10.1002/1097-0142(196611)19:11<1725::AID-CNCR2820191142>3.0.CO;2-T
Uzman B.G., Foley G.E., Farber S., Lazarus H.
Morphologic variations in human leukemic lymphoblasts (CCRF-CEM cells) after long-term culture and exposure to chemotherapeutic agents. A study with the electron microscope.
Cancer 19:1725-1742(1966)

Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.
The animal cell culture collection.
In Vitro 5:1-16(1970)

PubMed=4363409; DOI=10.1084/jem.139.5.1070
Kaplan J., Shope T.C., Peterson W.D. Jr.
Epstein-Barr virus-negative human malignant T-cell lines.
J. Exp. Med. 139:1070-1076(1974)

Kaplan J., Peterson W.D. Jr.
Detection of T-cell lymphoma-associated antigens on cord blood lymphocytes and phytohemagglutinin-stimulated blasts.
Cancer Res. 36:3471-3475(1976)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6198871; DOI=10.18926/AMO/32400
Oda T., Watanabe S., Nakamura T.
Type C virus particles produced in human T-cell lines derived from acute lymphoblastic leukemia and a leukemic T-lymphoid malignancy.
Acta Med. Okayama 37:529-533(1983)

PubMed=6600440; DOI=10.1007/BF02617996
Uittenbogaart C.H., Cantor Y., Fahey J.L.
Growth of human malignant lymphoid cell lines in serum-free medium.
In Vitro 19:67-72(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C.
Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=3495441; DOI=10.1002/eji.1830170503
Kanowith-Klein S., Saxon A., Uittenbogaart C.H.
Constitutive production of B cell differentiation factor-like activity by human T and B cell lines.
Eur. J. Immunol. 17:593-598(1987)

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=2144611; DOI=10.1128/mcb.10.10.5502-5509.1990
Cheng J., Haas M.
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.
Mol. Cell. Biol. 10:5502-5509(1990)

PubMed=2255914; DOI=10.1126/science.2255914
Aplan P.D., Lombardi D.P., Ginsberg A.M., Cossman J., Bertness V.L., Kirsch I.R.
Disruption of the human SCL locus by 'illegitimate' V-(D)-J recombinase activity.
Science 250:1426-1429(1990)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.
Interferon system defects in malignant T-cells.
Leukemia 8:425-434(1994)

Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)

PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608
Zhou M.-X., Yeager A.M., Smith S.D., Findley H.W.
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Blood 85:1608-1614(1995)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x
Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.
p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Eur. J. Haematol. 56:313-318(1996)

PubMed=9108419; DOI=10.1182/blood.V89.8.2986
Findley H.W., Gu L.-B., Yeager A.M., Zhou M.-X.
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Blood 89:2986-2993(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9557624; DOI=10.1038/sj.leu.2400976
Mattii L., Barale R., Petrini M.
Use of the comet test in the evaluation of multidrug resistance of human cell lines.
Leukemia 12:627-632(1998)

PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=9787181; DOI=10.1182/blood.V92.9.3410
Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.
PTEN gene alterations in lymphoid neoplasms.
Blood 92:3410-3415(1998)

PubMed=9823951; DOI=10.1038/sj.leu.2401198
Zhou M.-X., Gu L.-B., Yeager A.M., Findley H.W.
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Leukemia 12:1756-1763(1998)

PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7
Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.
Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies.
Leuk. Res. 23:19-27(1999)

PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5
Kawamura M., Ohnishi H., Guo S.-X., Sheng X.-M., Minegishi M., Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M., Sekiya T., Hayashi Y.
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Leuk. Res. 23:115-126(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

Martin-Aragon S., Mukherjee S.K., Taylor B.J., Ivy S.P., Fu C.H., Ardi V.C., Avramis V.I.
Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Anticancer Res. 20:139-150(2000)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=11565033; DOI=10.1038/35095068
Moberg K.H., Bell D.W., Pronk-Wahrer D.C.R., Haber D.A., Hariharan I.K.
Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines.
Nature 413:311-316(2001)

Nagel S., Kaufmann M., Drexler H.G., MacLeod R.A.F.
The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2).
Cancer Res. 63:5329-5334(2003)

PubMed=15472075; DOI=10.1126/science.1102160
Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Science 306:269-271(2004)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

Anagnostopoulos A.K., Vougas K., Kolialexi A., Mavrou A., Fountoulakis M., Tsangaris G.T.
The protein profile of the human immature T-cell line CCRF-CEM.
Cancer Genomics Proteomics 2:271-299(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17117183; DOI=10.1038/sj.bjc.6603447
Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J., Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Br. J. Cancer 95:1537-1544(2006)

PubMed=17170727; DOI=10.1038/sj.leu.2404486
Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M., De Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M., Langerak A.W.
Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.
Leukemia 21:230-237(2007)

PubMed=17308084; DOI=10.1158/0008-5472.CAN-06-2615
Nagel S., Scherr M., Kel A., Hornischer K., Crawford G.E., Kaufmann M., Meyer C., Drexler H.G., MacLeod R.A.F.
Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
Cancer Res. 67:1461-1471(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22675565; DOI=10.1371/journal.pone.0038463
Atak Z.K., De Keersmaecker K., Gianfelici V., Geerdens E., Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G., Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P., Cools J., Aerts S.
High accuracy mutation detection in leukemia on a selected panel of cancer genes.
PLoS ONE 7:E38463-E38463(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25070259; DOI=10.1186/1471-2407-14-547
Yamauchi T., Uzui K., Nishi R., Shigemi H., Ueda T.
Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
BMC Cancer 14:547.1-547.9(2014)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29718670; DOI=10.1021/acs.jproteome.8b00165
Clark D.J., Hu Y.-W., Bocik W., Chen L.-J., Schnaubelt M., Roberts R.R., Shah P., Whiteley G.R., Zhang H.
Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.
J. Proteome Res. 17:2205-2215(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=35354797; DOI=10.1038/s41467-022-29224-5
Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T., Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E., Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I., Lehtio J., Vesterlund M., Jafari R.
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.
Nat. Commun. 13:1691.1-1691.19(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections (Providers) AddexBio; C0003001/32
ATCC; CRL-7916 - Discontinued
ATCC; CRL-8436 - Discontinued
BCRC; 60137
BCRJ; 0063
CLS; 300147
Coriell; GM03671
ECACC; 85112105
JCRB; IFO50412
KCLB; 10119
NCBI_Iran; C105
RCB; RCB1980
TKG; TKG 0563
Cell line databases/resources CLO; CLO_0002334
CLO; CLO_0015478
CLO; CLO_0050143
MCCL; MCC:0000096
MCCL; MCC:0000097
CLDB; cl675
CLDB; cl676
CLDB; cl677
cancercelllines; CVCL_0207
Cell_Model_Passport; SIDM00121
Cosmic-CLP; 905952
DepMap; ACH-001738
DSMZCellDive; ACC-240
Lonza; 647
Anatomy/cell type resources BTO; BTO:0000736
Biological sample resources BioSample; SAMN00808493
BioSample; SAMN01821675
BioSample; SAMN03471121
BioSample; SAMN03471203
BioSample; SAMN03472050
BioSample; SAMN03472700
BioSample; SAMN03472808
BioSample; SAMN03473385
CRISP screens repositories BioGRID_ORCS_Cell_line; 1318
Chemistry resources ChEMBL-Cells; CHEMBL3307641
ChEMBL-Targets; CHEMBL382
ChEMBL-Targets; CHEMBL393
GDSC; 905952
PharmacoDB; CCRFCEM_190_2019
PubChem_Cell_line; CVCL_0207
Encyclopedic resources Wikidata; Q54809015
Experimental variables resources EFO; EFO_0002128
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM2116
GEO; GSM50193
GEO; GSM50257
GEO; GSM236780
GEO; GSM236816
GEO; GSM743457
GEO; GSM750806
GEO; GSM799345
GEO; GSM799408
GEO; GSM1153416
GEO; GSM1178011
GEO; GSM1178012
GEO; GSM1178013
GEO; GSM1181330
GEO; GSM1181347
GEO; GSM1374445
GEO; GSM1669670
GEO; GSM2124653
GEO; GSM5137708
Polymorphism and mutation databases Cosmic; 683716
Cosmic; 721708
Cosmic; 801728
Cosmic; 846384
Cosmic; 850198
Cosmic; 875863
Cosmic; 897449
Cosmic; 905952
Cosmic; 913411
Cosmic; 919157
Cosmic; 922674
Cosmic; 932765
Cosmic; 933544
Cosmic; 974251
Cosmic; 1012060
Cosmic; 1037690
Cosmic; 1044252
Cosmic; 1070703
Cosmic; 1071876
Cosmic; 1092595
Cosmic; 1115588
Cosmic; 1118462
Cosmic; 1127261
Cosmic; 1151774
Cosmic; 1175854
Cosmic; 1176599
Cosmic; 1191691
Cosmic; 1224367
Cosmic; 1226857
Cosmic; 1247870
Cosmic; 1281365
Cosmic; 1305336
Cosmic; 1330503
Cosmic; 1375587
Cosmic; 1483363
Cosmic; 1509201
Cosmic; 1523831
Cosmic; 1524793
Cosmic; 1639635
Cosmic; 1664520
Cosmic; 1760519
Cosmic; 1998437
Cosmic; 2165706
Cosmic; 2301560
Cosmic; 2361364
Cosmic; 2433754
Cosmic; 2458763
Cosmic; 2462863
Cosmic; 2602911
Cosmic; 2649235
Cosmic; 2649237
Cosmic; 2668294
IARC_TP53; 13197
IARC_TP53; 21218
Progenetix; CVCL_0207
Proteomic databases PRIDE; PXD005940
PRIDE; PXD005942
PRIDE; PXD005946
PRIDE; PXD023662
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number49